By FDA's count, novel drug approvals were up more than 30% in 2008, to a respectable 24. Unfortunately, the number of Innovative Commercial Therapies was no better than it has been for the past four years. But it could have been worse.
By Michael McCaughan
In today’s regulatory climate, even a glass half-full has to be
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.
HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.
